$68.57
0.23% yesterday
Nasdaq, Apr 17, 10:08 pm CET
ISIN
US2521311074
Symbol
DXCM
Sector

DexCom, Inc. Stock price

$68.57
-2.78 3.90% 1M
-0.98 1.41% 6M
-9.20 11.83% YTD
-65.29 48.77% 1Y
-51.59 42.93% 3Y
-12.28 15.19% 5Y
+51.72 306.94% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-0.16 0.23%
ISIN
US2521311074
Symbol
DXCM
Sector

Key metrics

Market capitalization $26.89b
Enterprise Value $26.89b
P/E (TTM) P/E ratio 48.13
EV/FCF (TTM) EV/FCF 42.64
EV/Sales (TTM) EV/Sales 6.67
P/S ratio (TTM) P/S ratio 6.67
P/B ratio (TTM) P/B ratio 12.74
Revenue growth (TTM) Revenue growth 11.34%
Revenue (TTM) Revenue $4.03b
EBIT (operating result TTM) EBIT $600.00m
Free Cash Flow (TTM) Free Cash Flow $630.70m
Cash position $2.58b
EPS (TTM) EPS $1.42
P/E forward 34.85
P/S forward 5.84
EV/Sales forward 5.84
Short interest 3.60%
Show more

Create a Free Account to create an DexCom, Inc. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

DexCom, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a DexCom, Inc. forecast:

24x Buy
83%
5x Hold
17%

Analyst Opinions

29 Analysts have issued a DexCom, Inc. forecast:

Buy
83%
Hold
17%

Financial data from DexCom, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4,033 4,033
11% 11%
100%
- Direct Costs 1,595 1,595
19% 19%
40%
2,438 2,438
7% 7%
60%
- Selling and Administrative Expenses 1,068 1,068
7% 7%
26%
- Research and Development Expense 552 552
10% 10%
14%
818 818
4% 4%
20%
- Depreciation and Amortization 218 218
17% 17%
5%
EBIT (Operating Income) EBIT 600 600
0% 0%
15%
Net Profit 576 576
6% 6%
14%

In millions USD.

Don't miss a Thing! We will send you all news about DexCom, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DexCom, Inc. Stock News

Neutral
GlobeNewsWire
about 21 hours ago
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DexCom, Inc. (NASDAQ: DXCM) on behalf of long-term stockholders following a class action complaint that was filed against DexCom on August 21, 2024 with a Class Period from January 8, 2024 to July 25, 2024. Our investigation con...
Neutral
CNBC
2 days ago
What Johnson & Johnson and Eli Lilly are saying about Trump's pharmaceutical tariffs, and Dexcom scores FDA approval for its glucose monitoring system.
Neutral
GlobeNewsWire
2 days ago
SAN DIEGO, April 16, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws.
More DexCom, Inc. News

Company Profile

DexCom, Inc. is a medical device manufacturing company. The firm engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Head office United States
CEO Kevin Sayer
Employees 10,300
Founded 1999
Website www.dexcom.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today